Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Lifemine Therapeutics is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, SHOWALTER, ALEXANDER KEITH, in 1 distinct art unit. SHOWALTER, ALEXANDER KEITH is the busiest examiner, with 1 busiest examiner pending action. This indicates a singular point of contact for the company's current pending patent matters.
The focus on 1 distinct examiner within the Biotechnology & Pharmaceuticals sector allows for a specialized prosecution strategy. With 1 pending office action, the company can focus its efforts on the specific requirements of SHOWALTER, ALEXANDER KEITH. The presence of 1 distinct art unit suggests that the technology is grouped within a single specialized area of the patent office. This centralized structure simplifies the management of the portfolio and reduces the need for diverse prosecution tactics. Since 1 busiest examiner pending action represents the entire workload, the applicant can expect a consistent examination experience.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549061 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18549061 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATMENT THEREOF | SHOWALTER, ALEXANDER KEITH | 1629 | §112 | Final Rejection | 60d overdue | Pending | Sep 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial